HWHao Wu

Hao Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hao Wu has a total of 194 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaojie Huang

    Center for Infectious Diseases, Beijing You'an Hospital, Capital Medical University, Beijing, China

    12 shared publications
  • Tong Zhang

    Department of Urology, Beijing Youan Hospital, Capital Medical University, Beijing, China

    11 shared publications
  • Hui Chen

    School of Biomedical Engineering, Capital Medical University, Beijing, China

    8 shared publications
  • Aixin Song

    Center for Infectious Diseases, Beijing You'an Hospital, Capital Medical University, Beijing, China

    7 shared publications
  • Wei Xia

    Department of Urology, Beijing Youan Hospital, Capital Medical University, Beijing, China

    7 shared publications
  • Xinchao Liu

    Department of Infectious Diseases, Peking Union Medical College Hospital, Beijing, China

    6 shared publications

Latest Publications

  • Open Access

    Real-world effectiveness of doravirine-containing antiretroviral therapy in Chinese adults living with HIV-1: a retrospective study

    by Hai Long, Xinping Yang, Shenghua He, Jun Liu, Renfang Zhang, Lijun Sun, Hongxin Zhao, Yuanqiu Li, Yaqun Fu, Kathryn Peebles, et al.

    Background: Doravirine (DOR)-containing antiretroviral therapy (ART) has been recommended as first-line ART by China treatment guidelines since 2021. However, Real-world studies on DOR in China are scarce. We evaluated the real-world effectiveness of DOR-containing ART in Chinese people with HIV-1 (PWH), including treatment-naïve people regardless of viral load (VL) at baseline and treatment-experienced people regardless if they were virologic suppression (VS) or not. Methods: This was a retrospective, multicenter, observational study using medical chart review in seven hospitals, covering top-tier infectious disease hospitals across regions in China. All the participants who initiated DOR-containing ART during August 2021 and September 2023 were included and followed until September 2024. Results: At baseline, higher proportions of the 352 participants were male (84.9%), from west region (78.7%), and mean age was 40.0 years. Of the 271 participants with available VL data to confirm the achievement of VS at week 48 ± 8 (271/352), 22.1% were treatment-naïve and 77.9% had prior antiretroviral experience. The adherence rate of DOR in the regimen or DOR/3TC/TDF single tablet was ≥ 80% in 91.5% of participants. Overall, DOR-containing ART achieved a VS rate of 93.7% (95% confidence interval: 90.8%, 96.6%), with rates of 90.0% and 94.8% observed in treatment-naïve and treatment-experienced participants, respectively. Notably, among all six treatment-experienced people who were unsuppressed at baseline, 100% of participants were suppressed at week 48 ± 8. DOR-containing ART appeared to be well tolerated among Chinese PWH, with an adverse event profile consistent with that described in product label. Conclusion: DOR-containing ART is an effective treatment for Chinese PWH in real-world settings, regardless of their VLs and treatment experience at baseline. Clinical trial number: Though it’s a non-interventional study, we basically followed registration rule for clinical trials, i.e., the registration/posting date would end up being prior to the actual start of any data collection/analysis. Thus in our study, the registration/posting date in EUPAS (registration number: EUPAS103993) and NMPA (registration number: CTR20231040) website was 23 Mar, 2023 and 10 Apr, 2023, respectively, which were prior to actual data collection date (July 2023). The registration and posting date was supposed to be the same date.

  • Plasma Cytokine Expression and Immune Reconstitution in Early and Delayed Anti-HIV 96-Weeks Treatment: A Retrospective Study

    by Chao Li, Jian-Ping Sun, Ni Wang, Ping Yan, Rui Wang, Bin Su, Tong Zhang, Hao Wu, Hui Chen, Zhen Li, et al.

    HIV is an immunodeficiency disease with emergence of inadequate corresponding reconstruction therapies. Pyroptosis of CD4+T cell is mainly caused by immune activation and inflammation that cannot be reduced by successful antiretroviral therapy (ART) alone. Co-infections because of CD4+T cell reconstitution failure can occur. Anti-inflammatory treatment determines the success of immune reconstitution. In our experiment, only a few cytokines could recover to normal level following with a 2-year antiretroviral treatment in early ART initiation, which is consistent with current findings about adjuvant HIV anti-inflammatory therapy. Early infection is often accompanied by a more severe inflammatory response. Innate immunity cytokines like GM-CSF, IP-10, and TNF-α exhibited the most elevated levels among all kinds of inflammatory cytokines. The correlation analysis showed at least eight cytokines contributing to the changes of CD4/CD8 ratio.


  • Open Access

    Increased HBV Coinfection and Decreased IFN-γ-Producing HBV-Specific CD8+ T Cell Numbers During HIV Disease Progression

    by Zhiqiang Zhu, Yuanyuan Qin, Qi Liang, Wei Xia, Tong Zhang, Wen Wang, Mengmeng Zhang, Taiyi Jiang, Hao Wu, Ye Tian

    Objective: To investigate the characteristics and mechanism of the dynamics of HBV infection with the progression of HIV disease and to explore the different responses of T lymphocytes to HBV in HIV patients in different stages of disease.Methods: We compared the rates and characteristics of HBV coinfection between 372 early HIV-infected and 306 chronically HIV-infected men who have sex with men (MSM) in the Beijing Youan Hospital from October 2006 to November 2014. We further analysed IFN-γ-producing HBV-specific CD8+ T cells in 15 early HIV-infected individuals and 20 chronic HIV-infected individuals with HBV coinfection.Results: Twenty-three HBsAg-positive cases were detected among the 372 early HIV-infected patients of this cohort, and the coinfection rate was 6.18%, while 35 HBsAg-positive cases were detected among the 306 chronically HIV-infected patients, with a coinfection rate of 11.44%. The coinfection rate of the chronically HIV-infected patients was significantly higher than that of the early-infected patients (p=0.0005). The median CD4+ T cell count in the early HIV infection patients was 445 cells/μL (196-1,030 cells/μL), which was higher than that in the chronic HIV infection patients [358 cells/μL (17-783 cells/μL)] (p<0.001). The proportion of IFN-γ-producing CD8+ T cells in early HIV-infected patients was significantly higher than that in chronically HIV-infected patients.Conclusion: The coinfection rate of HBV in HIV patients increases with HIV disease progression, which might be related to the decreased IFN-γ-producing HBV-specific CD8+ T cell numbers. The closely monitored HBV serum markers from the early stage of HIV infection are warranted.


  • Open Access

    Hsa-miR-31 Governs T-Cell Homeostasis in HIV Protection via IFN-γ-Stat1-T-Bet Axis

    by Lingyan Zhu, Chao Qiu, Lili Dai, Linxia Zhang, Meiqi Feng, Yu Yang, Chenli Qiu, Anli Zhang, Jun Huang, Ying Wang, et al.

    It remains poorly defined whether any human miRNAs play protective roles during HIV infection. Here, focusing on a unique cohort of HIV-infected former blood donors, we identified miR-31 (hsa-miR-31) by comparative miRNA profiling as the only miRNA inversely correlating with disease progression. We further validated this association in two prospective cohort studies. Despite conservation during evolution, hsa-miR-31, unlike its mouse counterpart (mmu-miR-31), was downregulated in human T cell upon activation. Our ex vivo studies showed that inhibiting miR-31 in naïve CD4+ T cells promoted a transcriptional profile with activation signature. Consistent with this skewing effect, miR-31 inhibition led to remarkably increased susceptibility to HIV infection. The suppressive nature of miR-31 in CD4+ T cell activation was pinpointed to its ability to decrease T-bet, the key molecule governing IFN-γ production and activation of CD4+ T cells, by directly targeting the upstream STAT1 transcriptional factor for downregulation, thus blunting Th1 response. Our results implicated miR-31 as a useful biomarker for tracking HIV disease progression and, by demonstrating its importance in tuning the activation of CD4+ T cells, suggested that miR-31 may play critical roles in other physiological contexts where the CD4+ T cell homeostasis needs to be deliberately controlled.


  • Open Access

    Advances and challenges in antiretroviral therapy for acquired immunodeficiency syndrome

    by Ruo-Jing Bai, Li-Li Dai, Hao Wu

    An abstract is unavailable. This article is available as a PDF only.


  • Open Access

    Efficacy and Safety of Raltegravir-Based Dual Therapy in AIDS Patients: A Meta-Analysis of Randomized Controlled Trials

    by Yinqiu Huang, Xiaojie Huang, Hui Chen, Hao Wu, Yaokai Chen

    Background: The life expectancy for HIV-infected individuals has improved dramatically because of improvements in antiretroviral therapy (ART). Today, a simplified two-drug regimen enhances adherence and treatment satisfaction by reducing adverse effects. Therefore, we need more evidence to show the benefits and risks of simplified ART regimens from randomized controlled trials (RCTs). We compared the efficacy and safety of raltegravir-based simplified dual therapy (DT) and of traditional triple therapy (TT) for people living with HIV/AIDS (PLWHA). Methods: We carried out a systematic review of RCTs. After using a combination of the key words “HIV,” “raltegravir,” and “protease inhibitor” to search the English-language electronic databases from January 1, 2004, to September 11, 2019, we pooled data across eligible studies and estimated the summary effect sizes with Review Manager (version 5.3). Results: We included eight RCTs involving 4420 PLWHA: 2187 (49.5%) received raltegravir-based simplified DT, and 2144 (48.5%) received traditional TT. The proportion of viral suppression was 79% at 48 weeks and 74% at 96 weeks in the simplified regimen, and the proportion of viral suppression was 78% at 48 weeks and 71% at 96 weeks in the traditional TT group. Furthermore, the proportion of viral suppression in the simplified DT group was greater than that in the TT group at 24 weeks (risk ratio 1.11, 95% confidence interval 1.02-1.21; p = 0.01). The CD4 cell counts in the simplified DT group were significantly higher at 48 weeks and 96 weeks than those in the group that received the traditional TT. Regarding adverse events and mortality rates, the DT and TT groups were similar. However, there was better adherence in the DT group than in the TT group. Conclusion: We found that the simplified regimen was noninferior to TT regimen in regard to viral suppression. Furthermore, the simplified DT regimen had a better CD4 cell count and lower adverse events than the TT regimen.


  • Dual effects of the novel ingenol derivatives on the acute and latent HIV-1 infections

    by He Yang, Xian Li, Xinyi Yang, Panpan Lu, Yanan Wang, Zhengtao Jiang, Hanyu Pan, Lin Zhao, Yuqi Zhu, Inam Ullah Khan, et al.


  • Open Access

    Psychometric Properties and Factor Structure of the Chinese Version of the Hospital Anxiety and Depression Scale in People Living With HIV

    by Zhiyuan Yang, Xiaojie Huang, Xinchao Liu, Jianhua Hou, Wenfang Wu, Aixin Song, Kathrine Meyers, Tong Zhang, Hui Chen, Hao Wu

    The population of people living with HIV (PLWH) is growing in number and usually has mental health problems that impact their quality of life. Therefore, valid instruments and screening methods for psychological disorders are of great significance. The Hospital Anxiety and Depression Scale (HADS) has good psychometric properties but shows ambiguous results in factor structure. This study aims to evaluate psychometric properties in terms of internal reliability and structure validity of the Chinese version of HADS (C-HADS) in a large sample of PLWH in China. The C-HADS was administered to 4102 HIV-infected adults at an HIV clinic in China. Exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) were performed to examine the factor structure. Measurement invariance was assessed across gender and course of infection. Internal reliability was also assessed. A bifactor model with anomalous loadings of item 7, 8 and 10 fits the data best and holds measurement invariance across gender and course of infection. Internal reliability was good with all Cronbach’s alphas > 0.70 and Spearman’s between 0.30 and 0.70. The C-HADS has good psychometric properties in terms of internal reliability and structure validity of a bifactor model. The C-HADS is recommended to be used as a total scale that measures general psychological distress instead of anxiety and depression separately when applied to PLWH. Further studies are needed to evaluate criterion validity and cut-off score as well as the effect of wording and scoring of the HADS.


  • Open Access

    Diagnostic effect of shear wave elastography imaging for differentiation of malignant liver lesions: a meta-analysis

    by Xing Hu, Xiaojie Huang, Hui Chen, Tong Zhang, Jianhua Hou, Aixin Song, Lei Ding, Weiyuan Liu, Hao Wu, Fankun Meng

    Shear wave elastography (SWE) imaging have been proposed for characterization of focal liver lesions. We conducted a meta-analysis to evaluate the accuracy and clinical utility of SWE imaging for differentiation of malignant and benign hepatic lesions. PubMed, Embase, Web of Science, and the Cochrane Library were systematically reviewed to search for studies published between January 1, 1990, and November 30, 2018. The studies published in English relating to the evaluation the diagnostic accuracy of SWE imaging for distinguishing malignant and benign liver lesions were retrieved and examined for pooled sensitivity, specificity, likelihood ratios, and diagnostic odds ratios, using bivariate random-effects models. The hierarchical summary receiver operating characteristic (HSROC) curve was estimated to assess the SWE imaging accuracy. The clinical utility of SWE imaging for differentiation of malignant liver lesions was evaluated by Fagan plot. A total of 15 studies, involving 1894 liver lesions in 1728 patients, were eligible for the meta-analysis. The pooled sensitivity and specificity for identification of malignant liver lesions were 0.82 (95% CI: 0.77–0.86) and 0.82 (95% CI: 0.76–0.87), respectively. The AUC was 0.89 (95% CI: 0.86–0.91). When the pre-test probability was 50%, after SWE imaging measurement over the cut-off value (positive result), the corresponding post-test probability for the presence of malignant liver lesions was 82%; the post-test probability was 18% after negative measurement. SWE imaging showed high sensitivity and specificity in differentiating malignant and benign liver lesions and may be promising for noninvasive evaluation of liver lesions. The review was registered in the International Prospective Register of Systematic Reviews (PROSPERO): CRD42018104510 .


  • Open Access

    Efficacy and Safety of Oral TDF-Based Pre-exposure Prophylaxis for Men Who Have Sex With Men: A Systematic Review and Meta-Analysis

    by Xiaojie Huang, Jianhua Hou, Aixin Song, Xinchao Liu, Xiaodong Yang, Junjie Xu, Jing Zhang, Qinghai Hu, Hui Chen, Yaokai Chen, et al.

    Background: Pre-exposure prophylaxis (PrEP) is used as an HIV prevention method by people at substantial risk of HIV infection. This systematic review and meta-analysis evaluates current clinical evidence for use of oral TDF-based PrEP among men who have sex with men. Methods: A comprehensive literature search in PubMed, web of science, Google Scholar and ClinicalTrials.gov was performed. A random-effects meta-analysis was conducted using the event rate (ER) for estimation of the incidence of HIV and grade 3 or 4 adverse events (AE) among PrEP arm and using risk ratio (RR) for comparison of incidence of HIV and grade 3 or 4 AE between PrEP recipients and PrEP non-users. Blood-based adherence levels were also divided into three categories with reference to previous meta-analysis. Subgroup meta-analysis was also performed to evaluate whether blood-based adherence levels moderated the effect of TDF-based PrEP on HIV incidence. Narrative review was used due to inconsistent measurements of risk behavior and drug resistance. This review is registered on the PROSPERO database (CRD42017077965). Results: Fourteen studies were included in the review. Oral TDF-based PrEP significantly reduced HIV incidence with minimum drug resistance and tolerable safety risks (HIV incidence, ER = 1.1%, 95% CI 0.6–2.0%, p < 0.001, RR = 0.244, 95% CI 0.111–0.537, p < 0.001 and grade 3 or 4 AEs, ER = 13.0%, 95% CI 9.9–16.9%, p < 0.001, RR = 1.059, 95% CI 0.824–1.362, p = 0.653). Oral TDF-based PrEP was more effective in reducing HIV incidence with high levels of blood-based PrEP adherence (ER, 0.4%) compared to moderate adherence (2.9%; p < 0.001). Most studies found no association between PrEP use and self-reported sexual behavior. Conclusion: Oral TDF-based PrEP is an effective intervention to prevent against HIV infection among MSM. Well-designed implementation science studies that integrate sociobehavioral and biomedical interventions are needed to identify optimal PrEP delivery models in different populations to translate biomedical efficacy into real-world efficacy.